{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T07:21:47Z","timestamp":1791098507307,"version":"4.1.0"},"reference-count":184,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Stem Cell"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.stem.2025.05.008","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T10:44:55Z","timestamp":1749120295000},"page":"878-894","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["Hallmarks of MSCs: Key quality attributes for pharmacology and clinical use"],"prefix":"10.1016","volume":"32","author":[{"given":"Sowmya","family":"Viswanathan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9374-1996","authenticated-orcid":false,"given":"Jacques","family":"Galipeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.stem.2025.05.008_bib1","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.stem.2018.05.004","article-title":"Mesenchymal stromal cells: clinical challenges and therapeutic opportunities","volume":"22","author":"Galipeau","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.stem.2025.05.008_bib2","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41556-019-0308-3","article-title":"Engineering a haematopoietic stem cell niche by revitalizing mesenchymal stromal cells","volume":"21","author":"Nakahara","year":"2019","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.stem.2025.05.008_bib3","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1146\/annurev-immunol-032712-095919","article-title":"Mesenchymal Stem Cell: Keystone of the Hematopoietic Stem Cell Niche and a Stepping-Stone for Regenerative Medicine","volume":"31","author":"Frenette","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.stem.2025.05.008_bib4","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.stem.2015.02.019","article-title":"Mesenchymal Cell Contributions to the Stem Cell Niche","volume":"16","author":"Kfoury","year":"2015","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.stem.2025.05.008_bib5","unstructured":"European Medicines Agency (EMA) (2024). Alofisel withdrawn from the EU market. https:\/\/www.ema.europa.eu\/en\/news\/alofisel-withdrawn-eu-market."},{"key":"10.1016\/j.stem.2025.05.008_bib6","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.jcyt.2020.11.007","article-title":"Mesenchymal stromal cell variables influencing clinical potency: the impact of viability, fitness, route of administration and host predisposition","volume":"23","author":"Galipeau","year":"2021","journal-title":"Cytotherapy"},{"key":"10.1016\/j.stem.2025.05.008_bib7","doi-asserted-by":"crossref","DOI":"10.1111\/acel.12933","article-title":"An early-senescence state in aged mesenchymal stromal cells contributes to hematopoietic stem and progenitor cell clonogenic impairment through the activation of a pro-inflammatory program","volume":"18","author":"Gnani","year":"2019","journal-title":"Aging Cell"},{"key":"10.1016\/j.stem.2025.05.008_bib8","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jcyt.2015.11.008","article-title":"International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials","volume":"18","author":"Galipeau","year":"2016","journal-title":"Cytotherapy"},{"key":"10.1016\/j.stem.2025.05.008_bib9","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/j.jcyt.2019.08.002","article-title":"Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT\u00ae) Mesenchymal Stromal Cell committee position statement on nomenclature","volume":"21","author":"Viswanathan","year":"2019","journal-title":"Cytotherapy"},{"key":"10.1016\/j.stem.2025.05.008_bib10","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1634\/stemcells.2005-0008","article-title":"Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells","volume":"24","author":"Krampera","year":"2006","journal-title":"Stem Cells"},{"key":"10.1016\/j.stem.2025.05.008_bib11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/bmb\/ldt031","article-title":"The angiogenic properties of mesenchymal stem\/stromal cells and their therapeutic potential","volume":"108","author":"Watt","year":"2013","journal-title":"Br. Med. Bull."},{"key":"10.1016\/j.stem.2025.05.008_bib12","doi-asserted-by":"crossref","first-page":"4619","DOI":"10.1182\/blood-2003-11-3909","article-title":"Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation","volume":"103","author":"Meisel","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.stem.2025.05.008_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2249.2012.04623.x","article-title":"CD73 and adenosine generation in the creation of regulatory microenvironments","volume":"171","author":"Regateiro","year":"2013","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.stem.2025.05.008_bib14","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1365-2249.2010.04256.x","article-title":"Inflammatory conditions affect gene expression and function of human adipose tissue-derived mesenchymal stem cells","volume":"162","author":"Crop","year":"2010","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.stem.2025.05.008_bib15","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.semcdb.2019.10.014","article-title":"Anti-fibrotic mechanisms of exogenously-expanded mesenchymal stromal cells for fibrotic diseases","volume":"101","author":"Rockel","year":"2020","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.stem.2025.05.008_bib16","article-title":"The dual role of mesenchymal stem cells in apoptosis regulation","volume":"15","author":"Chen","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.stem.2025.05.008_bib17","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1359\/jbmr.1999.14.7.1115","article-title":"Age-related osteogenic potential of mesenchymal stromal stem cells from human vertebral bone marrow","volume":"14","author":"D\u2019Ippolito","year":"1999","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.stem.2025.05.008_bib18","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/(SICI)1097-4644(19991201)75:3<424::AID-JCB8>3.0.CO;2-8","article-title":"Donor variation in the growth properties and osteogenic potential of human marrow stromal cells","volume":"75","author":"Phinney","year":"1999","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.stem.2025.05.008_bib19","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1089\/scd.2016.0218","article-title":"Different Donors Mesenchymal Stromal Cells Secretomes Reveal Heterogeneous Profile of Relevance for Therapeutic Use","volume":"26","author":"Assoni","year":"2017","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.stem.2025.05.008_bib20","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1634\/stemcells.2005-0342","article-title":"Comparative Analysis of Mesenchymal Stem Cells from Bone Marrow, Umbilical Cord Blood, or Adipose Tissue","volume":"24","author":"Kern","year":"2006","journal-title":"Stem Cells"},{"key":"10.1016\/j.stem.2025.05.008_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2015.00560","article-title":"Comparing the Immunomodulatory Properties of Bone Marrow, Adipose Tissue, and Birth-Associated Tissue Mesenchymal Stromal Cells","volume":"6","author":"Mattar","year":"2015","journal-title":"Front. Immunol."},{"key":"10.1016\/j.stem.2025.05.008_bib22","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1089\/scd.2011.0722","article-title":"Same or Not the Same? Comparison of Adipose Tissue-Derived Versus Bone Marrow-Derived Mesenchymal Stem and Stromal Cells","volume":"21","author":"Strioga","year":"2012","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.stem.2025.05.008_bib23","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/stcltm\/szab005","article-title":"Improved MSC Minimal Criteria to Maximize Patient Safety: A Call to Embrace Tissue Factor and Hemocompatibility Assessment of MSC Products","volume":"11","author":"Moll","year":"2022","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.stem.2025.05.008_bib24","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.molmed.2018.12.006","article-title":"Intravascular Mesenchymal Stromal\/Stem Cell Therapy Product Diversification: Time for New Clinical Guidelines","volume":"25","author":"Moll","year":"2019","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.stem.2025.05.008_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.839844","article-title":"Mesenchymal Stromal Cells for Enhancing Hematopoietic Engraftment and Treatment of Graft-Versus-Host Disease, Hemorrhages and Acute Respiratory Distress Syndrome","volume":"13","author":"Ringd\u00e9n","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.stem.2025.05.008_bib26","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1002\/stem.1976","article-title":"Hypoxic preconditioning of mesenchymal stromal cells induces metabolic changes, enhances survival, and promotes cell retention in vivo","volume":"33","author":"Beegle","year":"2015","journal-title":"Stem Cells"},{"key":"10.1016\/j.stem.2025.05.008_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2021.621748","article-title":"Increased Mesenchymal Stem Cell Functionalization in Three-Dimensional Manufacturing Settings for Enhanced Therapeutic Applications","volume":"9","author":"Kouroupis","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.stem.2025.05.008_bib28","doi-asserted-by":"crossref","DOI":"10.1186\/s13287-018-0876-3","article-title":"Changes in phenotype and differentiation potential of human mesenchymal stem cells aging in vitro","volume":"9","author":"Yang","year":"2018","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.stem.2025.05.008_bib29","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/j.stem.2021.09.006","article-title":"Mesenchymal stromal cells: Putative microenvironmental modulators become cell therapy","volume":"28","author":"Krampera","year":"2021","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.stem.2025.05.008_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam7828","article-title":"Apoptosis in mesenchymal stromal cells induces in vivo recipient-mediated immunomodulation","volume":"9","author":"Galleu","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.stem.2025.05.008_bib31","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/stem.2779","article-title":"Immunomodulation By Therapeutic Mesenchymal Stromal Cells (MSC) Is Triggered Through Phagocytosis of MSC By Monocytic Cells","volume":"36","author":"de Witte","year":"2018","journal-title":"Stem Cells"},{"key":"10.1016\/j.stem.2025.05.008_bib32","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.bbmt.2011.07.023","article-title":"Long-Term Complications, Immunologic Effects, and Role of Passage for Outcome in Mesenchymal Stromal Cell Therapy","volume":"18","author":"von Bahr","year":"2012","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.stem.2025.05.008_bib33","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1164\/rccm.201701-0107CP","article-title":"Fifty Years of Research in ARDS. Cell-based Therapy for Acute Respiratory Distress Syndrome. Biology and Potential Therapeutic Value","volume":"196","author":"Laffey","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.stem.2025.05.008_bib34","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S2213-2600(21)00218-6","article-title":"The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity","volume":"9","author":"Osuchowski","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.stem.2025.05.008_bib35","doi-asserted-by":"crossref","DOI":"10.1186\/s13054-022-04287-4","article-title":"The safety and efficacy of mesenchymal stromal cells in ARDS: a meta-analysis of randomized controlled trials","volume":"27","author":"Wang","year":"2023","journal-title":"Crit. Care"},{"key":"10.1016\/j.stem.2025.05.008_bib36","doi-asserted-by":"crossref","DOI":"10.1186\/s13287-022-02796-1","article-title":"Safety and long-term improvement of mesenchymal stromal cell infusion in critically COVID-19 patients: a randomized clinical trial","volume":"13","author":"Rebelatto","year":"2022","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.stem.2025.05.008_bib37","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.jcyt.2022.07.010","article-title":"An International Society for Cell and Gene Therapy Mesenchymal Stromal Cells Committee editorial on overcoming limitations in clinical trials of mesenchymal stromal cell therapy for coronavirus disease-19: time for a global registry","volume":"24","author":"Weiss","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.stem.2025.05.008_bib38","doi-asserted-by":"crossref","unstructured":"Kirkham, A.M., Bailey, A.J.M., Monaghan, M., Shorr, R., Lalu, M.M., Fergusson, D.A., and Allan, D.S. (2022). Updated living systematic review and meta-analysis of controlled trials of mesenchymal stromal cells to treat COVID-19: A framework for accelerated synthesis of trial evidence for rapid approval\u2014FASTER approval. Stem Cells Transl. Med. 11, 675\u2013687. https:\/\/academic.oup.com\/stcltm\/article\/11\/7\/675\/6618504?login=false.","DOI":"10.1093\/stcltm\/szac038"},{"key":"10.1016\/j.stem.2025.05.008_bib39","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-024-05358-6","article-title":"Efficacy and safety of mesenchymal stem cells therapy in COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials","volume":"22","author":"Lu","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.stem.2025.05.008_bib40","unstructured":"Mesoblast. Ninety Day Survival Outcomes in COVID-19 ARDS Trial of Remestemcel-L Presented at ISCT Meeting on Advances in Cell & Gene Therapies for Lung Diseases. https:\/\/www.globenewswire.com\/news-release\/2021\/07\/19\/2264530\/0\/en\/Ninety-Day-Survival-Outcomes-in-COVID-19-ARDS-Trial-of-Remestemcel-L-Presented-at-ISCT-Meeting-on-Advances-in-Cell-Gene-Therapies-for-Lung-Diseases.html."},{"key":"10.1016\/j.stem.2025.05.008_bib41","unstructured":"Athersys Inc.Athersys extends Near term liquidity with proceeds from warrant inducement and global ARDS license with Healios to explore strategic alternatives. https:\/\/www.athersys.com\/investors\/press-releases\/press-release-details\/2023\/Athersys-Extends-Near-Term-Liquidity-with-Proceeds-from-Warrant-Inducement-and-Global-ARDS-License-with-Healios-to-Explore-Strategic-Alternatives\/default.aspx."},{"key":"10.1016\/j.stem.2025.05.008_bib42","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jcyt.2022.03.006","article-title":"Mesenchymal stromal cell therapy for acute respiratory distress syndrome due to coronavirus disease 2019","volume":"24","author":"Whittaker Brown","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.stem.2025.05.008_bib43","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s00134-021-06570-4","article-title":"Safety and efficacy of multipotent adult progenitor cells in acute respiratory distress syndrome (MUST-ARDS): a multicentre, randomised, double-blind, placebo-controlled phase 1\/2 trial","volume":"48","author":"Bellingan","year":"2022","journal-title":"Intensive Care Med."},{"key":"10.1016\/j.stem.2025.05.008_bib44","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nm.1905","article-title":"Bone marrow stromal cells attenuate sepsis via prostaglandin E2\u2014dependent reprogramming of host macrophages to increase their interleukin-10 production","volume":"15","author":"N\u00e9meth","year":"2009","journal-title":"Nat. Med."},{"key":"10.1016\/j.stem.2025.05.008_bib45","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1164\/rccm.202201-0157OC","article-title":"A Randomized Trial of Mesenchymal Stromal Cells for Moderate to Severe Acute Respiratory Distress Syndrome from COVID-19","volume":"207","author":"Bowdish","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.stem.2025.05.008_bib46","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM200005043421801","article-title":"Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome","volume":"342","author":"Brower","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.stem.2025.05.008_bib47","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.chest.2020.11.050","article-title":"Corticosteroid Therapy Is Associated With Improved Outcome in Critically Ill Patients With COVID-19 With Hyperinflammatory Phenotype","volume":"159","author":"Chen","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.stem.2025.05.008_bib48","unstructured":"Mesoblast. Survival outcomes in COVID-19 ARDS patients treated with REMESTEMCEL-L. https:\/\/investorsmedia.mesoblast.com\/static-files\/527b8bf4-ed8f-433f-a767-89a9c13ce451."},{"key":"10.1016\/j.stem.2025.05.008_bib49","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.537","article-title":"The interaction between mesenchymal stem cells and steroids during inflammation","volume":"5","author":"Chen","year":"2014","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.stem.2025.05.008_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.943333","article-title":"Translating MSC Therapy in the Age of Obesity","volume":"13","author":"Boland","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.stem.2025.05.008_bib51","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/sctm.20-0099","article-title":"Treatment of chronic GvHD with mesenchymal stromal cells induces durable responses: A phase II study","volume":"9","author":"Boberg","year":"2020","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.stem.2025.05.008_bib52","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1186\/s13287-019-1449-9","article-title":"Tissue immune profiles supporting response to mesenchymal stromal cell therapy in acute graft-versus-host disease-a gut feeling","volume":"10","author":"Gavin","year":"2019","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.stem.2025.05.008_bib53","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41423-020-0402-2","article-title":"Functional exhaustion of antiviral lymphocytes in COVID-19 patients","volume":"17","author":"Zheng","year":"2020","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.stem.2025.05.008_bib54","article-title":"Immune dysfunction leads to mortality and organ injury in patients with COVID-19 in China: insights from ERS-COVID-19 study","volume":"5","author":"Li","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.stem.2025.05.008_bib55","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/cid\/ciaa248","article-title":"Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China","volume":"71","author":"Qin","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.stem.2025.05.008_bib56","unstructured":"Athersys Inc. (2020) Athersys announces commencement of patient enrollment in the MACOVIA study, a pivotal Phase 2\/3 trial evaluating MultiStem\u00ae cell therapy for COVID-19 induced ARDS. https:\/\/www.athersys.com\/investors\/press-releases\/press-release-details\/2020\/Athersys-Announces-Commencement-of-Patient-Enrollment-in-the-MACOVIA-Study-a-Pivotal-Phase-23-Trial-Evaluating-MultiStem-Cell-Therapy-for-COVID-19-Induced-ARDS\/default.aspx."},{"key":"10.1016\/j.stem.2025.05.008_bib57","unstructured":"Healios. (2021) Top Line Results of the ONE-BRIDGE Study in Patients with ARDS. https:\/\/moneyworld.jp\/discl-pdf\/tdnet\/2021080548046701GENERAL.pdf."},{"key":"10.1016\/j.stem.2025.05.008_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01952","article-title":"A Comparison of Phenotypic and Functional Properties of Mesenchymal Stromal Cells and Multipotent Adult Progenitor Cells","volume":"10","author":"Khan","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.stem.2025.05.008_bib59","unstructured":"Masters, R. Second Quarter MultiStem Clinical Trial Updates."},{"key":"10.1016\/j.stem.2025.05.008_bib60","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1093\/stcltm\/szad056","article-title":"Attitudes Towards Standardization of Mesenchymal Stromal Cells\u2014A Qualitative Exploration of Expert Views","volume":"12","author":"Wilson","year":"2023","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.stem.2025.05.008_bib61","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/14653240600855905","article-title":"Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement","volume":"8","author":"Dominici","year":"2006","journal-title":"Cytotherapy"},{"key":"10.1016\/j.stem.2025.05.008_bib62","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.stem.2014.01.013","article-title":"MSC-Based Product Characterization for Clinical Trials: An FDA Perspective","volume":"14","author":"Mendicino","year":"2014","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.stem.2025.05.008_bib63","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.jcyt.2023.04.005","volume":"25","author":"Viswanathan","year":"2023","journal-title":"Cytotherapy"},{"key":"10.1016\/j.stem.2025.05.008_bib64","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-054740","article-title":"Establishment of a consensus definition for mesenchymal stromal cells (MSC) and reporting guidelines for clinical trials of MSC therapy: a modified Delphi study protocol","volume":"11","author":"Renesme","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.stem.2025.05.008_bib65","doi-asserted-by":"crossref","DOI":"10.1186\/s13287-021-02435-1","article-title":"Characterisation of mesenchymal stromal cells in clinical trial reports: analysis of published descriptors","volume":"12","author":"Wilson","year":"2021","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.stem.2025.05.008_bib66","unstructured":"O\u2019Shea, O., Chapman, C., Klair, H., Abranches, E., Vessillier, S., Saraiva, L.D.J., Rigsby, P., and Price, J. WHO\/BS\/2019.2376 Collaborative Study to assess the suitability of the candidate WHO IRR for MSC identity (for flow cytometry) for advance therapies. https:\/\/www.who.int\/publications\/m\/item\/WHO-BS-2019.2376."},{"key":"10.1016\/j.stem.2025.05.008_bib67","year":"2020","journal-title":"Remestemcel-L for treatment of steroid refractory acute graft versus host disease in pediatric patients (FDA)"},{"key":"10.1016\/j.stem.2025.05.008_bib68","unstructured":"Mesoblast. (2023) Key outcomes from FDA type A meeting and mesoblast next steps to achieve Ryoncil approval. https:\/\/investorsmedia.mesoblast.com\/static-files\/adfc1ba0-bd4d-47bd-b0a0-a0b3516b0520."},{"key":"10.1016\/j.stem.2025.05.008_bib69","unstructured":"United States Department of Health and Human Services (2011). Guidance for Industry Potency Tests for Cellular and Gene Therapy Products."},{"key":"10.1016\/j.stem.2025.05.008_bib70","unstructured":"Center for Biologics Evaluation and Research (2023). Potency Assurance for Cellular and Gene Therapy Products. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/potency-assurance-cellular-and-gene-therapy-products."},{"key":"10.1016\/j.stem.2025.05.008_bib71","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/(SICI)1097-4644(199702)64:2<278::AID-JCB11>3.0.CO;2-F","article-title":"Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation","volume":"64","author":"Bruder","year":"1997","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.stem.2025.05.008_bib72","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S0301-472X(00)00160-0","article-title":"Proliferation kinetics and differentiation potential of ex vivo expanded human bone marrow stromal cells: Implications for their use in cell therapy","volume":"28","author":"Banfi","year":"2000","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.stem.2025.05.008_bib73","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.stemcr.2017.01.024","article-title":"Lessons Learned from Pioneering Neural Stem Cell Studies","volume":"8","author":"Temple","year":"2017","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.stem.2025.05.008_bib74","unstructured":"42 USC 262. Regulation of biological products. https:\/\/uscode.house.gov\/view.xhtml?req=granuleid:USC-2007-title42-section262&num=0&edition=2007."},{"key":"10.1016\/j.stem.2025.05.008_bib75","unstructured":"21 CFR 601.2. Applications for biologics licenses; procedures for filing. https:\/\/www.ecfr.gov\/current\/title-21\/part-601\/section-601.2."},{"key":"10.1016\/j.stem.2025.05.008_bib76","unstructured":"CFR Title 21. Food and Drugs 21 CFR \u00a7 601.2 Findlaw. https:\/\/codes.findlaw.com\/cfr\/title-21-food-and-drugs\/cfr-sect-21-601-2\/."},{"key":"10.1016\/j.stem.2025.05.008_bib77","unstructured":"21 CFR \u00a7 601.20. Biologics licenses; issuance and conditions (LII \/ Legal Information Institute). https:\/\/www.law.cornell.edu\/cfr\/text\/21\/601.20."},{"key":"10.1016\/j.stem.2025.05.008_bib78","unstructured":"Mesoblast Remestemcel-L for Treatment of Steroid Refractory Acute Graft versus Host Disease in Pediatric Patients. Meeting date: August 13, 2020, available for Public Disclosure."},{"key":"10.1016\/j.stem.2025.05.008_bib79","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/eji.201343668","article-title":"Human mesenchymal stromal cells modulate T-cell responses through TNF-\u03b1-mediated activation of NF-\u03baB","volume":"44","author":"Dorronsoro","year":"2014","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.stem.2025.05.008_bib80","unstructured":"GlobeNewsWire. (2024) Mesoblast resubmits biologic license application (BLA) with United States Food & drug administration (FDA) for approval of RYONCIL\u00ae in children with steroid-refractory acute graft-versus-host disease (SR-aGVHD). https:\/\/www.globenewswire.com\/news-release\/2024\/7\/9\/2910025\/0\/en\/Mesoblast-Resubmits-Biologics-License-Application-BLA-with-United-States-Food-Drug-Administration-FDA-for-Approval-of-Ryoncil-in-Children-with-Steroid-Refractory-Acute-Graft-Versus.html."},{"key":"10.1016\/j.stem.2025.05.008_bib81","unstructured":"FDA (2024). FDA Approves First Mesenchymal Stromal Cell Therapy to Treat Steroid-refractory Acute Graft-versus-host Disease. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-mesenchymal-stromal-cell-therapy-treat-steroid-refractory-acute-graft-versus-host."},{"key":"10.1016\/j.stem.2025.05.008_bib82","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/DCR.0b013e318255364a","article-title":"Autologous expanded adipose-derived stem cells for the treatment of complex cryptoglandular perianal fistulas: a phase III randomized clinical trial (FATT 1: fistula Advanced Therapy Trial 1) and long-term evaluation","volume":"55","author":"Herreros","year":"2012","journal-title":"Dis. Colon Rectum"},{"key":"10.1016\/j.stem.2025.05.008_bib83","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1016\/S0140-6736(16)31203-X","article-title":"Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn\u2019s disease: a phase 3 randomised, double-blind controlled trial","volume":"388","author":"Pan\u00e9s","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.stem.2025.05.008_bib84","unstructured":"Summary of Product Characteristics: Alofisel (darvadstrocel) suspension for injection. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/alofisel-epar-product-information_en.pdf."},{"key":"10.1016\/j.stem.2025.05.008_bib86","unstructured":"European Medicines Agency (2008). Guideline on human cell-based medicinal products. https:\/\/www.ema.europa.eu\/en\/human-cell-based-medicinal-products-scientific-guideline."},{"key":"10.1016\/j.stem.2025.05.008_bib88","unstructured":"European Medicines Agency (2006). Q 6 B Specifications: Test Procedures and Acceptance Criteria for Biotechnological\/Biological Products. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-q-6-b-test-procedures-and-acceptance-criteria-biotechnologicalbiological-products-step-5_en.pdf."},{"key":"10.1016\/j.stem.2025.05.008_bib89","doi-asserted-by":"crossref","first-page":"i191","DOI":"10.1093\/ecco-jcc\/jjad212.0106","article-title":"DOP66 INSPIRE: Preliminary data from an observational post-marketing registry on the effectiveness and safety of darvadstrocel in patients with Crohn\u2019s Disease and complex perianal fistulas","volume":"18","author":"Fathallah","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.stem.2025.05.008_bib90","doi-asserted-by":"crossref","first-page":"i34","DOI":"10.1093\/ecco-jcc\/jjad212.0018","article-title":"OP18 Efficacy and safety of darvadstrocel treatment in patients with complex perianal fistulas and Crohn\u2019s Disease: results from the global ADMIRE-CD II phase 3 study","volume":"18","author":"Serclova","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.stem.2025.05.008_bib91","unstructured":"FirstWord PHARMA. (2023) Takeda\u2019s US ambitions for Alofisel take a hit on key study failure. https:\/\/firstwordpharma.com\/story\/5790815."},{"key":"10.1016\/j.stem.2025.05.008_bib92","doi-asserted-by":"crossref","first-page":"985","DOI":"10.3324\/haematol.2015.140368","article-title":"Mesenchymal stromal cells from pooled mononuclear cells of multiple bone marrow donors as rescue therapy in pediatric severe steroid-refractory graft-versus-host disease: a multicenter survey","volume":"101","author":"Ku\u00e7i","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.stem.2025.05.008_bib93","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/s41409-018-0102-z","article-title":"Effective treatment of steroid and therapy-refractory acute graft-versus-host disease with a novel mesenchymal stromal cell product (MSC-FFM)","volume":"53","author":"Bader","year":"2018","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.stem.2025.05.008_bib94","unstructured":"Study Details | Treatment Of Steroid-Refractory Acute Graft-versus-host Disease With Mesenchymal Stromal Cells Versus Best Available Therapy (ClinicalTrials.gov). https:\/\/clinicaltrials.gov\/study\/NCT04629833."},{"key":"10.1016\/j.stem.2025.05.008_bib95","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-62544-8","article-title":"Advantages of pooling of human bone marrow-derived mesenchymal stromal cells from different donors versus single-donor MSCs","volume":"14","author":"Kannan","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.stem.2025.05.008_bib96","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1177\/03635465231180323","article-title":"Efficacy and Safety of Stempeucel in Osteoarthritis of the Knee: A Phase 3 Randomized, Double-Blind, Multicenter, Placebo-Controlled Study","volume":"51","author":"Gupta","year":"2023","journal-title":"Am. J. Sports Med."},{"key":"10.1016\/j.stem.2025.05.008_bib97","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-016-1195-7","article-title":"Efficacy and safety of adult human bone marrow-derived, cultured, pooled, allogeneic mesenchymal stromal cells (Stempeucel\u00ae): preclinical and clinical trial in osteoarthritis of the knee joint","volume":"18","author":"Gupta","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.stem.2025.05.008_bib98","doi-asserted-by":"crossref","first-page":"689","DOI":"10.5966\/sctm.2016-0237","article-title":"Administration of Adult Human Bone Marrow-Derived, Cultured, Pooled, Allogeneic Mesenchymal Stromal Cells in Critical Limb Ischemia Due to Buerger\u2019s Disease: Phase II Study Report Suggests Clinical Efficacy","volume":"6","author":"Gupta","year":"2017","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.stem.2025.05.008_bib99","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13287-024-03746-9","article-title":"A phase I\/II clinical trial of ex-vivo expanded human bone marrow derived allogeneic mesenchymal stromal cells in adult patients with perianal fistulizing Crohn\u2019s Disease","volume":"15","author":"Swaroop","year":"2024","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.stem.2025.05.008_bib100","unstructured":"ImmuneBio. created_by_alias Clinical Stage Immunology Company - Immune Bio. https:\/\/inmunebio.com\/index.php\/en\/."},{"key":"10.1016\/j.stem.2025.05.008_bib101","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.stem.2010.11.011","article-title":"A Mesoderm-Derived Precursor for Mesenchymal Stem and Endothelial Cells","volume":"7","author":"Vodyanik","year":"2010","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.stem.2025.05.008_bib102","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41591-020-1050-x","article-title":"Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study","volume":"26","author":"Bloor","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.stem.2025.05.008_bib103","doi-asserted-by":"crossref","first-page":"881","DOI":"10.3390\/ijms24010881","article-title":"iPSC-Derived MSCs Are a Distinct Entity of MSCs with Higher Therapeutic Potential than Their Donor-Matched Parental MSCs","volume":"24","author":"Lee","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.stem.2025.05.008_bib104","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s13238-012-2922-8","article-title":"The genomic stability of induced pluripotent stem cells","volume":"3","author":"Chen","year":"2012","journal-title":"Protein Cell"},{"key":"10.1016\/j.stem.2025.05.008_bib105","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1038\/s41591-024-02990-z","article-title":"Two-year safety outcomes of iPS cell-derived mesenchymal stromal cells in acute steroid-resistant graft-versus-host disease","volume":"30","author":"Kelly","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.stem.2025.05.008_bib106","unstructured":"ClinicalTrials.gov. (2025) Study Details | A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD. https:\/\/clinicaltrials.gov\/study\/NCT05643638."},{"key":"10.1016\/j.stem.2025.05.008_bib107","doi-asserted-by":"crossref","first-page":"16766","DOI":"10.1073\/pnas.1416121111","article-title":"TSG-6 as a biomarker to predict efficacy of human mesenchymal stem\/progenitor cells (hMSCs) in modulating sterile inflammation in vivo","volume":"111","author":"Lee","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.stem.2025.05.008_bib108","doi-asserted-by":"crossref","DOI":"10.4172\/2157-7633.1000365","article-title":"Quantifiable Metrics for Predicting MSC Therapeutic Efficacy","volume":"6","author":"Boregowda","year":"2016","journal-title":"J. Stem Cell Res. Ther."},{"key":"10.1016\/j.stem.2025.05.008_bib109","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adi2387","article-title":"TWIST1 and TSG6 are coordinately regulated and function as potency biomarkers in human MSCs","volume":"9","author":"Lee","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.stem.2025.05.008_bib110","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/stem.2322","article-title":"High Content Imaging of Early Morphological Signatures Predicts Long Term Mineralization Capacity of Human Mesenchymal Stem Cells upon Osteogenic Induction","volume":"34","author":"Marklein","year":"2016","journal-title":"Stem Cells"},{"key":"10.1016\/j.stem.2025.05.008_bib111","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.202310-1975OC","article-title":"Single-Cell RNA Sequencing Reveals Repair Features of Human Umbilical Cord Mesenchymal Stromal Cells","volume":"210","author":"Cyr-Depauw","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.stem.2025.05.008_bib112","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jcyt.2018.10.008","article-title":"Morphological profiling using machine learning reveals emergent subpopulations of interferon-\u03b3\u2013stimulated mesenchymal stromal cells that predict immunosuppression","volume":"21","author":"Marklein","year":"2019","journal-title":"Cytotherapy"},{"key":"10.1016\/j.stem.2025.05.008_bib113","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/bit.27974","article-title":"Morphological landscapes from high content imaging reveal cytokine priming strategies that enhance mesenchymal stromal cell immunosuppression","volume":"119","author":"Andrews","year":"2022","journal-title":"Biotechnol. Bioeng."},{"key":"10.1016\/j.stem.2025.05.008_bib114","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/j.jcyt.2024.03.100","article-title":"AUTOMATION AND PERFORMANCE-BASED SELECTION TO IMPROVE THE REPRODUCIBILITY OF MESENCHYMAL STROMAL CELL (MSC) FABRICATION","volume":"26","author":"Luangphakdy","year":"2024","journal-title":"Cytotherapy"},{"key":"10.1016\/j.stem.2025.05.008_bib115","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/2211068216676587","article-title":"Integrated Colony Imaging, Analysis, and Selection Device for Regenerative Medicine","volume":"22","author":"Kwee","year":"2017","journal-title":"SLAS Technol."},{"key":"10.1016\/j.stem.2025.05.008_bib116","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s10616-020-00403-w","article-title":"Automated in-process characterization and selection of cell-clones for quality and efficient cell manufacturing","volume":"72","author":"Mantripragada","year":"2020","journal-title":"Cytotechnology"},{"key":"10.1016\/j.stem.2025.05.008_bib117","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jcyt.2013.02.010","article-title":"Immunological characterization of multipotent mesenchymal stromal cells\u2014The International Society for Cellular Therapy (ISCT) working proposal","volume":"15","author":"Krampera","year":"2013","journal-title":"Cytotherapy"},{"key":"10.1016\/j.stem.2025.05.008_bib118","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.jcyt.2018.10.014","article-title":"Mesenchymal stromal cell therapy: progress in manufacturing and assessments of potency","volume":"21","author":"Robb","year":"2019","journal-title":"Cytotherapy"},{"key":"10.1016\/j.stem.2025.05.008_bib119","doi-asserted-by":"crossref","first-page":"575488","DOI":"10.3389\/fimmu.2020.575488","article-title":"Integrated Analysis of Transcriptome and Secretome From Umbilical Cord Mesenchymal Stromal Cells Reveal New Mechanisms for the Modulation of Inflammation and Immune Activation","volume":"11","author":"Cruz-Barrera","year":"2020","journal-title":"Front Immun."},{"key":"10.1016\/j.stem.2025.05.008_bib120","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1093\/stcltm\/szac050","article-title":"Chemokine Assay Matrix Defines the Potency of Human Bone Marrow Mesenchymal Stromal Cells","volume":"11","author":"Lipat","year":"2022","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.stem.2025.05.008_bib121","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/stem.3035","article-title":"Potency Analysis of Mesenchymal Stromal Cells Using a Phospho-STAT Matrix Loop Analytical Approach","volume":"37","author":"Chinnadurai","year":"2019","journal-title":"Stem Cells"},{"key":"10.1016\/j.stem.2025.05.008_bib122","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.917790","article-title":"Cytokine Activation Reveals Tissue-Imprinted Gene Profiles of Mesenchymal Stromal Cells","volume":"13","author":"Wiese","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.stem.2025.05.008_bib123","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/sctm.18-0070","article-title":"Commitment to Aerobic Glycolysis Sustains Immunosuppression of Human Mesenchymal Stem Cells","volume":"8","author":"Liu","year":"2019","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.stem.2025.05.008_bib124","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120257","article-title":"Effect of fatty acids on human bone marrow mesenchymal stem cell energy metabolism and survival","volume":"10","author":"Fillmore","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.stem.2025.05.008_bib125","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-65193-9","article-title":"Lactate preconditioning promotes a HIF-1\u03b1-mediated metabolic shift from OXPHOS to glycolysis in normal human diploid fibroblasts","volume":"10","author":"Kozlov","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.stem.2025.05.008_bib126","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jcyt.2021.08.002","article-title":"Metabolomics and cytokine profiling of mesenchymal stromal cells identify markers predictive of T-cell suppression","volume":"24","author":"Maughon","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.stem.2025.05.008_bib127","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1016\/j.jcyt.2022.06.001","article-title":"Longitudinal two-dimensional gas chromatography mass spectrometry as a non-destructive at-line monitoring tool during cell manufacturing identifies volatile features correlative to cell product quality","volume":"24","author":"Jimenez","year":"2022","journal-title":"Cytotherapy"},{"key":"10.1016\/j.stem.2025.05.008_bib128","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1093\/stmcls\/sxad039","article-title":"Development of a Robust Consensus Modeling Approach for Identifying Cellular and Media Metabolites Predictive of Mesenchymal Stromal Cell Potency","volume":"41","author":"Van Grouw","year":"2023","journal-title":"Stem Cells"},{"key":"10.1016\/j.stem.2025.05.008_bib129","doi-asserted-by":"crossref","DOI":"10.1186\/s13287-017-0553-y","article-title":"Immunosuppressive capacity of mesenchymal stem cells correlates with metabolic activity and can be enhanced by valproic acid","volume":"8","author":"Killer","year":"2017","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.stem.2025.05.008_bib130","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s13287-015-0127-9","article-title":"Age, atherosclerosis and type 2 diabetes reduce human mesenchymal stromal cell-mediated T-cell suppression","volume":"6","author":"Kizilay Mancini","year":"2015","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.stem.2025.05.008_bib131","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1161\/CIRCRESAHA.117.311400","article-title":"Mitochondrial Oxidative Stress Reduces the Immunopotency of Mesenchymal Stromal Cells in Adults With Coronary Artery Disease","volume":"122","author":"Kizilay Mancini","year":"2018","journal-title":"Circ. Res."},{"key":"10.1016\/j.stem.2025.05.008_bib132","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/stem.2272","article-title":"Human Adipose Stromal\/Stem Cells from Obese Donors Show Reduced Efficacy in Halting Disease Progression in the Experimental Autoimmune Encephalomyelitis Model of Multiple Sclerosis","volume":"34","author":"Strong","year":"2016","journal-title":"Stem Cells"},{"key":"10.1016\/j.stem.2025.05.008_bib133","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00977","article-title":"Metabolism in Human Mesenchymal Stromal Cells: A Missing Link Between hMSC Biomanufacturing and Therapy?","volume":"10","author":"Yuan","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.stem.2025.05.008_bib134","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s12276-023-00940-2","article-title":"Adipokines at the crossroads of obesity and mesenchymal stem cell therapy","volume":"55","author":"Pham","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.stem.2025.05.008_bib135","doi-asserted-by":"crossref","first-page":"e91","DOI":"10.1016\/S2665-9913(21)00326-X","article-title":"Safety and preliminary efficacy of allogeneic bone marrow-derived multipotent mesenchymal stromal cells for systemic sclerosis: a single-centre, open-label, dose-escalation, proof-of-concept, phase 1\/2 study","volume":"4","author":"Farge","year":"2022","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.stem.2025.05.008_bib136","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1089\/scd.2016.0068","article-title":"Inactivated Mesenchymal Stem Cells Maintain Immunomodulatory Capacity","volume":"25","author":"Luk","year":"2016","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.stem.2025.05.008_bib137","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-26834-3","article-title":"Mesenchymal stromal cell apoptosis is required for their therapeutic function","volume":"12","author":"Pang","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.stem.2025.05.008_bib138","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1016\/j.ymthe.2023.10.004","article-title":"Apoptosis in mesenchymal stromal cells activates an immunosuppressive secretome predicting clinical response in Crohn\u2019s disease","volume":"31","author":"Cheung","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.stem.2025.05.008_bib139","doi-asserted-by":"crossref","DOI":"10.1038\/s41420-025-02412-0","article-title":"Proinflammatory cytokines sensitise mesenchymal stromal cells to apoptosis","volume":"11","author":"Payne","year":"2025","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.stem.2025.05.008_bib140","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214107","article-title":"Iron nanoparticle-labeled murine mesenchymal stromal cells in an osteoarthritic model persists and suggests anti-inflammatory mechanism of action","volume":"14","author":"Hamilton","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.stem.2025.05.008_bib141","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.jcyt.2017.09.013","article-title":"Intramuscular administration potentiates extended dwell time of mesenchymal stromal cells compared to other routes","volume":"20","author":"Braid","year":"2018","journal-title":"Cytotherapy"},{"key":"10.1016\/j.stem.2025.05.008_bib142","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-021-03839-w","article-title":"Short lifespan of syngeneic transplanted MSC is a consequence of in vivo apoptosis and immune cell recruitment in mice","volume":"12","author":"Preda","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.stem.2025.05.008_bib143","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/sctm.18-0053","article-title":"Umbilical Cord-Derived Mesenchymal Stromal Cells (MSCs) for Knee Osteoarthritis: Repeated MSC Dosing Is Superior to a Single MSC Dose and to Hyaluronic Acid in a Controlled Randomized Phase I\/II Trial","volume":"8","author":"Matas","year":"2019","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.stem.2025.05.008_bib144","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-04801-7","article-title":"Circulating Biomarkers to Identify Responders in Cardiac Cell therapy","volume":"7","author":"Jokerst","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.stem.2025.05.008_bib145","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jacc.2022.11.061","article-title":"Randomized Trial of Targeted Transendocardial Mesenchymal Precursor Cell Therapy in Patients With Heart Failure","volume":"81","author":"Perin","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.stem.2025.05.008_bib146","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1182\/blood-2018-01-822957","article-title":"MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHD","volume":"131","author":"Major-Monfried","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.stem.2025.05.008_bib147","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1038\/s41409-021-01442-3","article-title":"Mesenchymal stromal cell therapy induces high responses and survival in children with steroid refractory GVHD and poor risk biomarkers","volume":"56","author":"Kasikis","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.stem.2025.05.008_bib148","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41423-023-01022-z","article-title":"Current perspectives on mesenchymal stromal cell therapy for graft versus host disease","volume":"20","author":"Kadri","year":"2023","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.stem.2025.05.008_bib149","doi-asserted-by":"crossref","DOI":"10.1186\/s13287-023-03443-z","article-title":"Efferocytosis of viable versus heat-inactivated MSC induces human monocytes to distinct immunosuppressive phenotypes","volume":"14","author":"Schrodt","year":"2023","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.stem.2025.05.008_bib150","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01228","article-title":"The Necrobiology of Mesenchymal Stromal Cells Affects Therapeutic Efficacy","volume":"10","author":"Weiss","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.stem.2025.05.008_bib151","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/stem.1118","article-title":"Analysis of Tissues Following Mesenchymal Stromal Cell Therapy in Humans Indicates Limited Long-Term Engraftment and No Ectopic Tissue Formation","volume":"30","author":"von Bahr","year":"2012","journal-title":"Stem Cells"},{"key":"10.1016\/j.stem.2025.05.008_bib152","doi-asserted-by":"crossref","DOI":"10.1186\/s12931-021-01734-8","article-title":"Effect of mesenchymal stromal cell infusions on lung function in COPD patients with high CRP levels","volume":"22","author":"Weiss","year":"2021","journal-title":"Respir. Res."},{"key":"10.1016\/j.stem.2025.05.008_bib153","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.joca.2022.08.019","article-title":"Knee osteoarthritis phenotypes based on synovial fluid immune cells correlate with clinical outcome trajectories","volume":"30","author":"Trajerova","year":"2022","journal-title":"Osteoarthr. Cartil."},{"key":"10.1016\/j.stem.2025.05.008_bib154","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/sctm.18-0183","article-title":"Bone Marrow Mesenchymal Stromal Cell Treatment in Patients with Osteoarthritis Results in Overall Improvement in Pain and Symptoms and Reduces Synovial Inflammation","volume":"8","author":"Chahal","year":"2019","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.stem.2025.05.008_bib155","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/annrheumdis-2015-208918","article-title":"Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib\/IIa clinical trial","volume":"76","author":"\u00c1lvaro-Gracia","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.stem.2025.05.008_bib156","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s10495-018-1474-7","article-title":"MiRNA-126 expression inhibits IL-23R mediated TNF-\u03b1 or IFN-\u03b3 production in fibroblast-like synoviocytes in a mice model of collagen-induced rheumatoid arthritis","volume":"23","author":"Gao","year":"2018","journal-title":"Apoptosis"},{"key":"10.1016\/j.stem.2025.05.008_bib157","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1111\/jcmm.12353","article-title":"Decreased expression of microRNA-21 correlates with the imbalance of Th17 and Treg cells in patients with rheumatoid arthritis","volume":"18","author":"Dong","year":"2014","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.stem.2025.05.008_bib158","article-title":"Integrated Analysis of MicroRNA and mRNA Expression Profiles in Rheumatoid Arthritis Synovial Monocytes","volume":"18","author":"Ji","year":"2011","journal-title":"J. Rheum. Dis."},{"key":"10.1016\/j.stem.2025.05.008_bib159","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.167402","article-title":"Local administration of mesenchymal stromal cells is safe and modulates the immune compartment in ulcerative proctitis","volume":"8","author":"Ouboter","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.stem.2025.05.008_bib160","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01244","article-title":"Dissecting Allo-Sensitization After Local Administration of Human Allogeneic Adipose Mesenchymal Stem Cells in Perianal Fistulas of Crohn\u2019s Disease Patients","volume":"10","author":"Avivar-Valderas","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.stem.2025.05.008_bib161","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/stcltm\/szad010","article-title":"Regulatory B Cells Contribute to the Clinical Response After Bone Marrow-Derived Mesenchymal Stromal Cell Infusion in Patients With Systemic Sclerosis","volume":"12","author":"Loisel","year":"2023","journal-title":"Stem Cells Transl. Med."},{"key":"10.1016\/j.stem.2025.05.008_bib162","doi-asserted-by":"crossref","first-page":"6074","DOI":"10.1158\/1078-0432.CCR-12-2603","article-title":"Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer","volume":"19","author":"Howe","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.stem.2025.05.008_bib163","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.94939","article-title":"NK cells in childhood obesity are activated, metabolically stressed, and functionally deficient","volume":"2","author":"Tobin","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.stem.2025.05.008_bib164","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/4297025","article-title":"Diet-Induced Obesity Is Associated with an Impaired NK Cell Function and an Increased Colon Cancer Incidence","volume":"2017","author":"B\u00e4hr","year":"2017","journal-title":"J. Nutr. Metab."},{"key":"10.1016\/j.stem.2025.05.008_bib165","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.clim.2016.01.007","article-title":"Alteration of Natural Killer cell phenotype and function in obese individuals","volume":"177","author":"Viel","year":"2017","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.stem.2025.05.008_bib166","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.cmet.2019.07.004","article-title":"Fatty Acid Metabolites Combine with Reduced \u03b2 Oxidation to Activate Th17 Inflammation in Human Type 2 Diabetes","volume":"30","author":"Nicholas","year":"2019","journal-title":"Cell Metab."},{"key":"10.1016\/j.stem.2025.05.008_bib167","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1016\/j.celrep.2020.01.047","article-title":"CCL2 and CXCL12 Derived from Mesenchymal Stromal Cells Cooperatively Polarize IL-10+ Tissue Macrophages to Mitigate Gut Injury","volume":"30","author":"Giri","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.stem.2025.05.008_bib168","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/stem.3380","article-title":"Macrophages at the nexus of mesenchymal stromal cell potency: The emerging role of chemokine cooperativity","volume":"39","author":"Galipeau","year":"2021","journal-title":"Stem Cells"},{"key":"10.1016\/j.stem.2025.05.008_bib169","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/imr.13074","article-title":"Extracellular vesicles and immune response during pregnancy: A balancing act","volume":"308","author":"Morelli","year":"2022","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.stem.2025.05.008_bib170","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.671093","article-title":"Placenta-Derived Exosomes as a Modulator in Maternal Immune Tolerance During Pregnancy","volume":"12","author":"Bai","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.stem.2025.05.008_bib171","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0012-1606(91)90336-2","article-title":"A pregnancy defect in the osteopetrotic (op\/op) mouse demonstrates the requirement for CSF-1 in female fertility","volume":"148","author":"Pollard","year":"1991","journal-title":"Dev. Biol."},{"key":"10.1016\/j.stem.2025.05.008_bib172","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1172\/JCI60561","article-title":"Macrophages regulate corpus luteum development during embryo implantation in mice","volume":"123","author":"Care","year":"2013","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.stem.2025.05.008_bib173","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jri.2005.05.002","article-title":"Lymphocyte phenotyping and NK cell activity analysis in pregnant NOD\/SCID mice","volume":"68","author":"Lin","year":"2005","journal-title":"J. Reprod. Immunol."},{"key":"10.1016\/j.stem.2025.05.008_bib174","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1161\/HYPERTENSIONAHA.118.10858","article-title":"Reduction in Regulatory T Cells in Early Pregnancy Causes Uterine Artery Dysfunction in Mice","volume":"72","author":"Care","year":"2018","journal-title":"Hypertension"},{"key":"10.1016\/j.stem.2025.05.008_bib175","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.placenta.2011.06.019","article-title":"Trophoblast deportation part II: a review of the maternal consequences of trophoblast deportation","volume":"32","author":"Pantham","year":"2011","journal-title":"Placenta"},{"key":"10.1016\/j.stem.2025.05.008_bib176","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41586-018-0392-8","article-title":"Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response","volume":"560","author":"Chen","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.stem.2025.05.008_bib177","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.yhbeh.2012.02.023","article-title":"Pregnancy and pregnancy-associated hormones alter immune responses and disease pathogenesis","volume":"62","author":"Robinson","year":"2012","journal-title":"Horm. Behav."},{"key":"10.1016\/j.stem.2025.05.008_bib178","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1182\/bloodadvances.2020001711","article-title":"Mesenchymal stromal cell therapeutic potency is dependent upon viability, route of delivery, and immune match","volume":"4","author":"Giri","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.stem.2025.05.008_bib179","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1002\/stem.1729","article-title":"Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties?","volume":"32","author":"Moll","year":"2014","journal-title":"Stem Cells"},{"key":"10.1016\/j.stem.2025.05.008_bib180","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.00458","article-title":"Human Mesenchymal Stromal Cell (MSC) Characteristics Vary Among Laboratories When Manufactured From the Same Source Material: A Report by the Cellular Therapy Team of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative","volume":"8","author":"Stroncek","year":"2020","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.stem.2025.05.008_bib181","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.stemcr.2014.05.003","article-title":"Actin cytoskeletal disruption following cryopreservation alters the biodistribution of human mesenchymal stromal cells in vivo","volume":"3","author":"Chinnadurai","year":"2014","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.stem.2025.05.008_bib182","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3109\/14653249.2011.623691","article-title":"Cryopreserved mesenchymal stromal cells display impaired immunosuppressive properties as a result of heat-shock response and impaired interferon-\u03b3 licensing","volume":"14","author":"Fran\u00e7ois","year":"2012","journal-title":"Cytotherapy"},{"key":"10.1016\/j.stem.2025.05.008_bib183","doi-asserted-by":"crossref","DOI":"10.1002\/jcb.30531","article-title":"Mechanotransduction and epigenetic modulations of chromatin: Role of mechanical signals in gene regulation","volume":"125","author":"Mishra","year":"2024","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.stem.2025.05.008_bib184","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcb.2023.151373","article-title":"Impact of heat and cold shock on epigenetics and chromatin structure","volume":"103","author":"Casali","year":"2024","journal-title":"Eur. J. Cell Biol."},{"key":"10.1016\/j.stem.2025.05.008_bib185","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1089\/scd.2016.0347","article-title":"Improved Post-Thaw Function and Epigenetic Changes in Mesenchymal Stromal Cells Cryopreserved Using Multicomponent Osmolyte Solutions","volume":"26","author":"Pollock","year":"2017","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.stem.2025.05.008_bib186","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1002\/stem.2415","article-title":"Cryopreserved Mesenchymal Stromal Cells Are Susceptible to T-Cell Mediated Apoptosis Which Is Partly Rescued by IFN\u03b3 Licensing","volume":"34","author":"Chinnadurai","year":"2016","journal-title":"Stem Cells"}],"container-title":["Cell Stem Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1934590925001882?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1934590925001882?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:31:26Z","timestamp":1762561886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1934590925001882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":184,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1934590925001882"],"URL":"https:\/\/doi.org\/10.1016\/j.stem.2025.05.008","relation":{},"ISSN":["1934-5909"],"issn-type":[{"value":"1934-5909","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hallmarks of MSCs: Key quality attributes for pharmacology and clinical use","name":"articletitle","label":"Article Title"},{"value":"Cell Stem Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.stem.2025.05.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}